Models of Patient Engagement for Alzheimer's Disease
October 13, 2019
MOPEAD partners meet in Cologne for final Consortium Meeting
MOPEAD partners from the University of Cologne hosted the 5th and last project Consortium meeting in their premises in Cologne (Germany), on the 1st and 2nd October 2019. The meeting was an opportunity for the Consortium members to hear about the project results at this very point in time and discuss their finalisation and dissemination . . .
Interim analysis of MOPEAD's online recruitment strategy presented at AAIC 2019
Cambridge Cognition attended the Alzheimer’s Association International Conference this month in Los Angeles (USA) and presented a poster showing an interim analysis of the online screening as a recruitment strategy if the Models of Patient Engagement in Alzheimer’s disease (MOPEAD) project . .
MOPEAD Project to be published in Azheimer's & Dementia: The Journal of the Alzheimer's Association
Today, the renowned journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association published an article on the foundations and the structure of the MOPEAD (Models Of Patient Engagement for Alzheimer’s Disease) project.
Članek o Projektu MOPEAD v reviji Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Danes je v priznani strokovni reviji Alzheimer's & Dementia, ki jo izdaja Alzheimer's Association iz Velike Britanije, objavljen članek o temeljih in strukturi projekta MOPEAD (Modeli vključevanja bolnikov z Alzheimerjevo boleznijo). [https://bit.ly/2V4KnI1]
The MOPEAD project has been featured in Pharma Fakten. Pharma Fakten is an initiative taken by pharmaceutical companies in Germany to provide quick and accurate information to the general public on current topics of interest to the pharmaceutical industry.
This year MOPEAD was at the CTAD Conference in Boston. A Focus Panel titled “Pre-screening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s disease for Clinical Trials” discussed mechanisms to identify individuals with earlier-stage disease in the general population and in primary care settings, communicate the nature of clinical research, expedite evaluation at the research site, and ensure good communication with primary care providers.
The MOPEAD consortium discusses project's progress in Berlin
The MOPEAD Consortium met in Berlin on 04/05 October 2017 after the Alzheimer Europe annual conference. The Consortium also invited a pool of external Advisors who enriched the MOPEAD implementation plan with their insight.
MOPEAD presented during the Alzheimer Europe annual conference in Berlin
Alzheimer Europe organised a Symposium supported by Eli Lilly on 4 October 2017 at its annual conference in Berlin. The symposium titled “Engaging with Patient Organizations within the IMI Consortia to inform quality, relevance and value in Alzheimer’s research – insights from MOPEAD, EPAD and ROADMAP" explored how these three public-private consortia sponsored by Horizon 2020 under the auspices of IMI and EFPIA, are tackling AD across its continuum.
MOPEAD engages citizens to seek early diagnosis for Alzheimer’s disease
GeriatricArea, a Spanish on-line information site for geriatricians, presents MOPEAD : El proyecto MOPEAD busca implicar a los ciudadanos en el diagnóstico precoz del Alzheimer (MOPEAD engages citizens to seek early diagnosis for Alzheimer’s disease)